Navigation
Company
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Contact Us
General Contact
For Healthcare Professionals
Careers
Archive: June, 2024
Home
2024
June
30
Jun
2024
A Phase 2, open-label, single-arm, prospective, multicenter study of
nab
-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
0
0
June 30, 2024
A Phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
June 30, 2024
28
Jun
2024
Antitumor activity of
nab
-sirolimus versus mTOR inhibitors temsirolimus, sirolimus, and everolimus in A549 NSCLC xenografts
0
0
June 28, 2024
Antitumor activity of nab-sirolimus versus mTOR inhibitors temsirolimus, sirolimus, and everolimus in A549 NSCLC xenografts
June 28, 2024
